Wealthy Americans Pay Up to $20,000 for Risky Ibogaine Retreats in Mexico
High-earning Americans are traveling to Mexico to pay up to $20,000 for ibogaine treatments, seeking relief from addiction, burnout, or performance issues despite significant cardiac risks. Clinics in Cancun and Playa del Carmen offer luxury retreats with medical supervision, though the drug remains illegal in the U.S. outside clinical trials. The trend gained attention after the death of Presley Gerber, who had undergone similar high-dose treatments. Experts warn that these unregulated therapies lack consistent safety standards and are not proven cures for substance use disorders.
Key points
- Ibogaine treatments in Mexico cost between $5,000 and $20,000, with luxury packages including lodging, yoga, and medical care.
- The drug is illegal in the United States outside of clinical trials, prompting Americans to travel to Mexico, Costa Rica, and other Latin American countries.
- Clinics in Playa del Carmen and Cancun market the substance for addiction recovery, burnout relief, and performance optimization.
- Ibogaine carries serious cardiac risks, and the intensity of the experience can last more than 24 hours.
- The number of clinics in Mexico offering ibogaine has grown from almost none a decade ago to at least 40 today.
Background
This trend follows the September 2026 death of Presley Gerber, son of model Cindy Crawford, who had traveled to Mexico for high-dose ibogaine treatment. Addiction specialist Dr. Drew Pinsky cited Gerber's use of the substance as a critical red flag, warning against patient-directed care with unapproved therapies. Ibogaine, a Schedule I substance derived from an African shrub, remains illegal in the U.S. outside of clinical trials due to its potential for fatal cardiac complications.
Why it matters
The rise of high-cost, unregulated psychedelic retreats highlights a growing demand for alternative mental health and addiction treatments among affluent Americans. However, the lack of standardized medical screening and emergency preparedness at these facilities poses serious safety risks. As the market expands, the gap between unproven therapeutic claims and potential life-threatening side effects raises concerns about patient safety and the regulation of cross-border medical tourism.
What to watch
Regulators and medical professionals may continue to scrutinize the safety and efficacy of ibogaine treatments as the number of clinics in Mexico and other Latin American countries grows. Public awareness of the risks associated with unregulated psychedelic therapies is likely to increase, particularly following high-profile deaths linked to such treatments.
Want the full story? Read the original reporting
Read on Fox News